ArticleJournal of clinical psychopharmacology
Metabolic Problems Among People With Treatment-Resistant Schizophrenia are Not Unique to Clozapine.
Article in Journal of clinical psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is unclear whether treatment with clozapine, when compared directly with other antipsychotics, is differentially associated with metabolic problems among people with treatment-resistant schizophrenia (TRS). We evaluated the prevalence of diabetes, dyslipidemia, obesity, and hypertension, and parameters such as glucose, lipids, weight, and blood pressure of people with TRS managed on clozapine and non-clozapine antipsychotics.
methodsDemographic, clinical, and metabolic data of patients with TRS who commenced clozapine between 2006 and 2016 at a public hospital were collected in 2023. Participants were divided into those who were on clozapine and those who had discontinued clozapine and were on other antipsychotics when the data were collected. Metabolic disorders of the 2 groups were compared with the t test, the χ 2 test, and the Mann-Whitney U test. The significance level was set at P <0.05.
resultsOne hundred six participants with TRS were on treatment with clozapine, and 41 with other antipsychotics. The participants' mean age was 44.3 (SD: 10.2) years, and 74.1% were males. Metabolic disorders such as dyslipidemia (45.6%), obesity (37.4%), and diabetes (22.1%) were prevalent among people with TRS. However, there was no significant difference in diabetes, obesity, and hypertension, and parameters such as blood sugar, lipid levels, and blood pressure between the clozapine and non-clozapine cohorts. While dyslipidaemia was significantly higher among those who were managed on clozapine, 75% of them were prescribed statins.
conclusionsA comprehensive approach addressing a broad range of risk factors, rather than solely focusing on clozapine, could be beneficial when evaluating and treating metabolic problems among people with TRS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.